Introduction
The p53 tumor suppressor gene plays a key role in maintaining genetic stability and protection against cancer. Accumulation and activation of functional p53 protein occurs in response to a variety of stresses and insults potentially leading to genetic alterations (Levine, 1997; Pugacheva et al., 2000) . Acting mainly (but not exclusively) as a sequence-specific transcription factor, p53 is capable of activating a set of genes required for cell cycle arrest or apoptosis (for review see el-Deiry (1998); Sionov et al. (1999) ). In this manner the p53 gene controls elimination of potential progenitors of malignant tumor cells. p53 deficient cells show greatly increased genetic instability, and most of the p53 knockout mice develop malignant diseases by 6 months of age (Donehower et al., 1992) . Different types of abnormalities in the p53 signaling pathways are observed in a majority of human malignancies. The most frequent type of defect represents missense mutations within the p53 gene itself. Unexpectedly a small fraction of mutations in the tumors corresponds to nonsense or frame shift mutations and that discriminates the p53 gene from other tumor-suppressors, such as RB or APC . This fact suggests that the presence of a mutated protein in addition to the loss of wild type p53 protein might confer selective growth advantage and promote clonal expansion (Greenblatt et al., 1994) . In contrast to a classical tumor suppressor gene, a missense mutation in the p53 gene can lead not only to loss of function (both in cis by mutation itself, or in trans by a dominantnegative mechanism), but also to a gain of function. In particular, novel activities of mutant p53 are capable of promoting tumorigenicity when introduced into p53-null cell types (Dittmer et al., 1993; Michalovitz et al., 1991) . Also, over-expression of mutant p53 proteins in p53-null cells of several lineages enhances their transformed properties and plating efficiency in culture, and increases tumorigenicity and tissue invasiveness in mice (Dittmer et al., 1993; Gloushankova et al., 1997; Hsiao et al., 1994; Kremenetskaya et al., 1997; Sun et al., 1993; Wolf et al., 1984) . Introduction into p53-null mice of a mutant p53 allele changes the tumor spectrum and results in higher frequencies of metas-tases (Liu et al., 2000) . Some of the p53 mutants provide increased resistance to p53-independent apoptosis induced by a variety of treatments, including certain chemotherapeutic drugs (Kremenetskaya et al., 1997; Li et al., 1998; Lotem and Sachs, 1995; Peled et al., 1996) . For example, in p53 negative lung carcinoma cell line H1299 introduction of His175 and His179 p53 mutants significantly reduces the rate of etoposideinduced apoptosis, although His273 and Trp248 mutants provide a much milder effect, indicating an allele specific impact, which provides further evidence that mutant p53 protein confers this activity (Blandino et al., 1999) .
The mechanisms underlying gain of function activities of p53 mutants remain poorly understood. Some studies emphasize the importance of the N-terminal transcription-activation domain for expression of mutant p53 gain of function phenotype (Lanyi et al., 1998; Lin et al., 1995) . Mutant p53s seem to be capable of activating promoters of genes that are usually not activated by the wild type protein. Among these are promoters of MDR1 (Chin et al., 1992; Dittmer et al., 1993; Kopnin et al., 1995) , PCNA (Deb et al., 1992) , HSP70 (Tsutsumi-Ishii et al., 1995), 15-lipoxygenase (Kelavkar and Badr, 1999) , BAG-1 (Yang et al., 1999) and c-myc (Frazier et al., 1998) genes. It is not clear whether mutant p53 acts directly as a transcription factor with altered sequence specificity, or modifies expression of the genes by interaction with factors responsible for positive or negative transcriptional regulation. Taking into account how common missense p53 mutants are in human cancer, it is clear that understanding the mechanisms underlying this gain of function as well as identification of genes that are regulated by p53 mutants may help in development of rational strategies of cancer treatment.
In a recent study using subtraction hybridization cloning we have isolated several cDNA clones corresponding to genes that are activated in p53-negative mouse fibroblast cell line 10(3) following expression of exogenous tumor-derived human mutant p53-His175 (Pugacheva et al., 2000) . One of the most abundant cDNAs differentially expressed in the 10(3)-p53His175 cell line corresponded to the mouse homolog of the dUTPase gene. dUTPase mediates conversion of dUTP to dUMP, which can then be used by thymidylate synthase (TS) for synthesis of dTMP. Thus, dUTPase lowers dUTP/dTTP ratio preventing mis-incorporation of uracil into DNA. Uracil misincorporation plays a leading role in cytotoxicity mediated by TS inhibitors, such as FUdR and a broadly used anticancer drug 5-FU (Aherne and Browne, 1999) . Inhibition of TS leads to increase in dUTP levels and incorporation of uracil into DNA. This initiates DNA excision repair process mediated by uracil-DNA glycosylase (Lindhal, 1982) . Massive DNA repair generates multiple DNA strand breaks that ultimately lead to cell death. Ectopic expression of dUTPase results in significant protection from FUdRinduced DNA strand breaks and increased viability over control cells (Canman et al., 1994) . Comparison of dUTPase expression in colon cancer showed its strong correlation with poor response to 5-FU therapy and a worse prognosis (Ladner et al., 2000) .
In this study we show that certain types of mutant p53s are capable of inducing expression of the dUTPase gene and, as a result, increasing resistance of cells to fluoropyrimidine drugs. This observation provides a possible mechanism for increased resistance of certain malignant tumors to 5-FU, and may have potential value for prediction of sensitivity to chemotherapy based on analysis of mutant p53 expression.
Results and discussion
We tested whether expression of different forms of tumor-derived p53 mutants introduced into p53 negative cells can affect dUTPase expression and sensitivity to 5-FU. Constitutive ectopic expression of His175 and Ala281 p53 mutants in p53-negative mouse cell line 10(3) results in significant increase in dUTPase transcripts as seen by Northern blot hybridization ( Figure 1a ). This result is consistent with the fact that the dUTPase cDNA clone was present in a high proportion of a subtraction library from 10(3)-His175 vs 10(3) cell lines.
Conditional expression vectors were then used to study immediate effects of mutant p53s. Various forms of mutant p53 cDNAs were inserted into selfinactivating retroviral vectors designed for tetracycline-regulated gene expression. Three different p53 deficient cell lines bearing a tetracycline dependent transactivator protein, tTA, were infected with recombinant retroviral stocks obtained after transfection of the DNA constructs into the packaging cell line Phoenix. Mass cultures obtained after selection with G418 were induced to express p53 by withdrawal of doxacycline from the medium. Twenty-four hours after induction, strong signals corresponding to p53 were seen on Western blots (Figure 1b,d ). In the mouse p53 deficient fibroblast cell line 10(1) induction of His175 p53 mutant expression correlated with a significant increase in the dUTPase transcript revealed by semiquantitative RT -PCR (Figure 1b) . Disruption of the transcriptional activation domain by a double mutation in amino acids 22 and 23 eliminated this effect indicating that this domain is required for induction of dUTPase. The effect was limited to mutant p53s, as wild type p53 expression did not increase dUTPase expression while increasing transcription of p21-Waf1. A similar response to expression of His175 mutant was observed in two p53-negative human cell lines derived from lung (H1299) and ovarian (SK-OV3) carcinoma cell lines (Figure 1c,d) . In SK-OV3 cells the importance of the transcriptional activation domain of p53 for induction of dUTpase was also demonstrated.
To test whether there could be some specific effects on dUTPase expression depending on the type of p53 missense mutation, two additional tumor derived hotspot mutant p53 cDNAs, His273 and Trp248, were expressed in p53 negative cells. While the Trp248 p53 mutant showed similar induction of dUTPase transcripts, there was no visible effect from His273 both in SK-OV3 (Figure 1d ) and H1299 cell lines (not shown). This differential effect of p53 mutants was specific for the dUTPase gene, as c-myc, another gene known to respond to p53 mutants (Frazier et al., 1998) was induced by all three mutants equally well (Figure 1d) . The result was similar with SK-OV3 and H1299 cell lines (not shown).
Next, we examined how the increase in dUTPase expression induced by p53 mutants affects sensitivity of cells to a chemotherapeutic drug 5-FU. Testing sensitivity to another chemotherapeutic drug, doxorubicin, was used as a control. In the 10(1) cells induction of the His175 p53 mutant resulted in a significant increase in the number of colonies formed in the presence of 5-FU, but no increase in colony formation was observed when a similar assay was performed with doxorubicin ( Figure 2a,b,c) . The His175 p53 mutant induced increase in colony formation in the presence of 5-FU was comparable with that observed with 10(1) cells expressing exogenous human dUTPase gene (Figure 2c) . Expression of His175 p53 mutant with a disrupted transcriptionalactivation domain (mutation in amino-acids 22 and 23) did not show any increase in 5-FU resistance. This result is in agreement with a lack of dUTPase induction in 10(1) cells expressing His175 mutant containing mutations in amino acids 22 and 23 ( Figure  1b) . Therefore, it is likely that an intact transcription activation domain is important for either direct or indirect induction of dUTPase expression leading to increased resistance to 5-FU. This result is also in good agreement with recent study showing that the integrity of N-terminal transcription domain of p53 is required RT -PCR analysis of the dUTPase transcripts in mouse cells 10(1) harboring tetracycline-regulated constructs expressing wt-p53, 22/23-p53, and 22/23/His175 p53 in the presence (+) and following 24 h after removal (7) of 1 mg/ ml of tetracycline. RT -PCR with p21-Waf1 primers was used as control for transcriptional activity of the wt-p53. Beta-actin primers were used for normalization of cDNA samples. (c) RT -PCR analysis of the dUTPase transcripts in human lung carcinoma cells H1299 harboring tetracycline-regulated wt-p53, His175 p53 and Trp248 p53. RT -PCR with primers specific for human p53 were used for control of induction of p53 expression. (d) RT -PCR analysis of the dUTPase transcripts in human ovary carcinoma cells SK-OV3 harboring tetracycline-regulated wt-p53, 22/23/His175 p53, His175, His273 p53 and Trp 248 p53. RT -PCR with primers specific for the human c-myc were used to monitor expression of one of the genes known to be upregulated by mutant p53s for mutant p53 interference with cisplatin-induced apoptosis (Matas et al., 2001) .
In two p53 negative human cell lines H1299 and SK-OV3, a good correlation was found between the ability of p53 mutants to increase expression of the dUTPase gene, and to increase number of colonies formed in the presence of 150 nM of 5-FU (Figure 2d,e) . The strongest increase in colony formation was observed with the His175 p53 mutant. Another p53 mutant, Trp248, was also capable of increasing the number of 5-FU resistant colonies, although the effect was moderate. In contrast, His273 p53 mutant overexpressed in SK-OV3 cells produced neither an increase in dUTPase transcripts nor increased survival of cells in the presence of 150 nM 5-FU (Figure 1d , and Figure  2e ). It should be noted that expression of either p53 mutants in the cell lines tested produced no changes in number of colonies formed in the presence of doxorubicin. Therefore, the effect was not due to some nonspecific increase in cell survival, but was limited to resistance to fluoropyrimidine drugs.
To test the possibility that treatment with 5-FU may result in preferential selection of mutant p53 expressing cells, an experiment was set up that monitors changes in proportion of different types of cells in cell mixtures after treatment with different drugs. 10(1) and 10(1)-His175 cells were labeled by introduction of retroviral construct expressing EGFP (pPS-EGFP-neo). Both types of fluorescent-labeled cells were mixed with an equal number of non-labeled cells expressing either p53 mutants (His175 or 22/23-His175), or exogenous human dUTPase in a sense or an anti-sense orientation. The cell mixtures were exposed to 150 nM of 5- (Figure 3b) . Therefore, although expression of dUTPase seems to be the major factor responsible for greater viability of cells in the presence of 5-FU, some additional activities of mutant p53 may contribute to the resistance. Other genes whose expression was altered by mutant p53s might mediate these activities. Treatment of similar cell mixtures with 15 nM of doxorubicin did not reveal any significant changes in proportion of EGFP-expressing cells (result not shown).
The results obtained in this study reveal a novel gain of function activity conferred by certain p53 mutants that directly links expression of mutant p53 activity with resistance to chemotherapeutic drugs of the fluoro-pyrimidine group. Clinical studies have revealed higher resistance to fluoropyrimidine therapy of tumors expressing p53 mutants (Benhattar et al., 1996; Cabelguenne et al., 2000; Zheng et al., 1999) . In several cases such effects of p53 mutants were attributed to dominant-negative suppression of the wild type p53 activity that resulted in abrogation of p53-induced apoptosis (Bunz et al., 1999) , and an increase in activity of the MDR1 gene (Bottini et al., 2000) . Clearly, induction of dUTPase by certain p53 mutants can additionally contribute to resistance to 5-FU therapy. It has yet to be established whether there is any correlation between the type of p53 mutation in human tumors and the outcome of 5-FU therapy. Differential effects of hot-spot p53 mutants on expression of dUTPase and resistance to 5-FU (His174 and Trp248 vs His273 mutants) indicate the potential value of information about a particular type of p53 mutation for the development of rational therapeutic schemes. Testing other types of p53 mutations are necessary to extend these observations, and to reveal common structural features required for this particular gain of function phenotype. Identification of dUTPase as a specific mutant p53 up-regulated gene may provide a basis for design of rational drugs and development of novel therapeutic strategies. In addition, these results validate the approach of studying p53 gain of function by identification of new transcriptional targets of mutant p53 and further direct testing of their contribution to the malignant phenotype.
Materials and methods

Cell lines
All cell lines were grown in DMEM supplemented with 10% FBS at 378C and 5% CO 2 . Mouse p53-null fibroblast cell lines 10(3) (Harvey and Levine, 1991) with introduced His175 and Ala281 p53 mutants under control of MuMLV LTR were described earlier (Pugacheva et al, 2000) . For tetracycline-regulated expression of p53 mutants, mouse 10(1) and 10(3) (Harvey and Levine, 1991) and human SK-OV3 (ATTC HTB-77) and NCI-H1299 (ATCC CRL-5803) p53-null cell lines were first infected with retroviral vector pPS-tTA-hygro expressing tetracycline-dependent transactivator protein tTA (Gossen and Bujard, 1992) . Selected functional tTA expressing clones were infected with self-inactivating retroviral vectors (pSIT-neo) carrying different mutant p53s (His175, Trp248, His273, Leu22/Trp23, His175/Leu22/Trp23) under control of a tetracycline-dependent promoter. G418-resistant cultures were selected and maintained in the presence of 250 ng/ml of doxycycline to suppress p53 expression. For induction of the p53 expression, the cells were incubated in doxycycline-free medium for 24 -48 h.
Western blot analysis
Cells were washed twice with PBS, scraped from Petri dishes in cold PBS followed by brief centrifugation. The 10(1) cell pellets were lysed in buffer (50 mM Tris-HCl pH7.5, 150 mM NaCl, 0.5% NP-40 and 1 mM EDTA with addition of 1 mM dithiothreitol, 100 mM PMSF, 1 mM pepstatin A and 1 mM E64). The SK-OV3 and H1299 cell pellets were lysed in the RIPA buffer. Equal amounts of total protein (approximately 600 mg) were used for overnight immunoprecipitation with the p53 specific monoclonal antibodies PAb421 cross-linked to Protein A-Sepharose CL4B at 48C. The precipitated proteins were separated on 10% SDS -PAAG electrophoresis, transferred onto Immobilon-P (Millipore) membrane, probed with the p53 specific monoclonal antibodies PAb421 and developed using peroxidase conjugated anti-mouse IgG and ECL-Plus Western blot reagents (Amersham).
Northern hybridization
Total RNA was isolated with Trizol reagent (GIBCO -BRL). Separation on 1% agarose gel, capillary transfer to Hybond-N membrane, and hybridization with a corresponding 32 Plabeled cDNA probes were performed according to published protocols (Sambrook et al., 1989) . Each sample applied on a gel contained 20 mg of total RNA. The dUTPase cDNA used as a probe was obtained by RACE PCR.
Semi-quantitative RT -PCR
cDNA was synthesized on 5 mg of total RNA, with oligo-(dT) 18 -23 primer and AMV reverse transcriptase according to manufacturer's recommendations (Amersham PLC). PCR amplifications were performed with primers that yield 126 bp fragment of the mouse dUTPase cDNA: 5'-AGCATTTGGT-GTTCTAGGATGCAGGA; 5'-ACCAAGTCTGCATGTCA-ATGCCATGCTC; 520 bp fragment of the human dUTPase cDNA: 5'-CGGGATCCCGCCTTCTGGCTCTGCCATGC-CCTGC-3'; 5'-GGAATTCGCATAAATTTTAATTCTTTC-CAGTG-3'; 5'-GGAATTCGCATAAATTTTAATTCTTTC-CAGTG-3', 278 bp fragment of mouse p21-WAF1 cDNA: 5'-CCGAGAACGGTGGAACTTTGA; 5'-GTTTTCGGCCCT-GAGATGTTG; 589 bp fragment of human c-myc cDNA: 5'-AAGATGAGGAAGAAAACGATGTTG; 5'-ACATTTCT-GTTAGAAGGAATCGT; and 604 bp fragment corresponding to the beta-actin cDNA: 5'-AAGATGACCCAGATCAT-GTTTGAGACC; 5'-GCAGTAATCTCCTTCTGCATCCT-GTCA. Amplification was carried out with HotTub DNA polymerase (Amersham) for 20, 25 and 30 cycles. The PCR products were separated by agarose gel electrophoresis.
Colonogenic survival assays of the mouse 10(1), the human SK-OV3 and H1299 cells with tetracycline-regulated expression of different p53 mutants were performed in 6-well plates. One610 3 for the 10(1) and the H1299 cells, 4610 3 for the SK-OV3 cells were seeded onto each well with and without 250 ng/ml of doxycycline. Forty-eight hours later the medium containing drugs at LD 90 concentration (for 10(1) 250 nM, for the SK-OV3 and the H1299 150 nM of 5-FU; and for the SK-OV3 1 nM, for 10(1) and the H1299 10 nM of doxorubicin) was added and changed every 4 days. Eighteen days later the cells were fixed with methanol, stained with Giemsa, and the number of colonies was counted. Quantitation of EGPF-positive cells by FACS. EGFP labeled cells were obtained by retroviral-mediated infection with supernatants of the packaging cell line Phoenix-ampho after lipofection of the pPS -EGFP retroviral vector. Five days after infection the cells were subjected to fluorescent activated cell sorting (FACS Vantage, BD). More than 90% of the cell populations obtained had maintained green fluorescence even after three weeks of further cultivation. The cells of corresponding EGFP negative and EGFP-positive lines were mixed in equal proportion (50 : 50) and were allowed to grow for 2 days. For the experiments 5610 4 cells of mixed cell populations were seeded onto 6-well plates with and without doxycycline. Twenty-four hours later half of the wells were treated with 250 nM of 5-FU. After an additional 24 h the cells were washed twice with PBS and fresh medium with doxycycline was added. After 5 -7 days of recovery the cultures approaching monolayer were spitted, and the percentage of the EGFP-positive cells was determined by FACS.
